Vincristine Sulfate Pfs

— THERAPEUTIC CATEGORIES —
  • Bladder, kidney, and other urologic cancers
  • Bone and connective tissue cancer
  • CNS cancers
  • Leukemias, lymphomas, and other hematologic cancers
PAGE CONTENTS
  • Jump to Section
  • Generic Name & Formulations
  • Indications
  • Dosage and Administration
  • Contraindications
  • Boxed Warnings
  • Warnings/Precautions
  • Pharmacokinetics
  • Interactions
  • Adverse Reactions
  • Clinical Trials
  • Note
  • Patient Counseling

    • Vincristine Sulfate Pfs Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

    Pharmacological Class

    Antimicrotubule agent.

    How Supplied

    Contact supplier

    Manufacturer

    Various generic manufacturers

    Vincristine Sulfate Pfs Indications

    Indications

    In combination with other chemotherapeutic agents for Wilms' tumor.

    Vincristine Sulfate Pfs Dosage and Administration

    Adult

    Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

    Children

    ≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

    Vincristine Sulfate Pfs Contraindications

    Contraindications

    Demyelinating form of Charcot-Marie-Tooth syndrome.

    Vincristine Sulfate Pfs Boxed Warnings

    Boxed Warning

    Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

    Vincristine Sulfate Pfs Warnings/Precautions

    Warnings/Precautions

    Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

    Vincristine Sulfate Pfs Pharmacokinetics

    See Literature

    Vincristine Sulfate Pfs Interactions

    Interactions

    Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

    Vincristine Sulfate Pfs Adverse Reactions

    Adverse Reactions

    GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

    Vincristine Sulfate Pfs Clinical Trials

    See Literature

    Vincristine Sulfate Pfs Note

    Notes

    Formerly known under the brand name Vincasar PFS.

    Vincristine Sulfate Pfs Patient Counseling

    See Literature

    Vincristine Sulfate Pfs Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

    Pharmacological Class

    Antimicrotubule agent.

    How Supplied

    Contact supplier

    Manufacturer

    Various generic manufacturers

    Vincristine Sulfate Pfs Indications

    Indications

    In combination with other chemotherapeutic agents for rhabdomyosarcoma.

    Vincristine Sulfate Pfs Dosage and Administration

    Adult

    Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

    Children

    ≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

    Vincristine Sulfate Pfs Contraindications

    Contraindications

    Demyelinating form of Charcot-Marie-Tooth syndrome.

    Vincristine Sulfate Pfs Boxed Warnings

    Boxed Warning

    Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

    Vincristine Sulfate Pfs Warnings/Precautions

    Warnings/Precautions

    Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

    Vincristine Sulfate Pfs Pharmacokinetics

    See Literature

    Vincristine Sulfate Pfs Interactions

    Interactions

    Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

    Vincristine Sulfate Pfs Adverse Reactions

    Adverse Reactions

    GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

    Vincristine Sulfate Pfs Clinical Trials

    See Literature

    Vincristine Sulfate Pfs Note

    Notes

    Formerly known under the brand name Vincasar PFS.

    Vincristine Sulfate Pfs Patient Counseling

    See Literature

    Vincristine Sulfate Pfs Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

    Pharmacological Class

    Antimicrotubule agent.

    How Supplied

    Contact supplier

    Manufacturer

    Various generic manufacturers

    Vincristine Sulfate Pfs Indications

    Indications

    In combination with other chemotherapeutic agents for neuroblastoma.

    Vincristine Sulfate Pfs Dosage and Administration

    Adult

    Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

    Children

    ≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

    Vincristine Sulfate Pfs Contraindications

    Contraindications

    Demyelinating form of Charcot-Marie-Tooth syndrome.

    Vincristine Sulfate Pfs Boxed Warnings

    Boxed Warning

    Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

    Vincristine Sulfate Pfs Warnings/Precautions

    Warnings/Precautions

    Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

    Vincristine Sulfate Pfs Pharmacokinetics

    See Literature

    Vincristine Sulfate Pfs Interactions

    Interactions

    Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

    Vincristine Sulfate Pfs Adverse Reactions

    Adverse Reactions

    GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

    Vincristine Sulfate Pfs Clinical Trials

    See Literature

    Vincristine Sulfate Pfs Note

    Notes

    Formerly known under the brand name Vincasar PFS.

    Vincristine Sulfate Pfs Patient Counseling

    See Literature

    Vincristine Sulfate Pfs Generic Name & Formulations

    Legal Class

    Rx

    General Description

    Vincristine sulfate 1mg/mL; soln for IV inj; contains mannitol; preservative-free.

    Pharmacological Class

    Antimicrotubule agent.

    How Supplied

    Contact supplier

    Manufacturer

    Various generic manufacturers

    Vincristine Sulfate Pfs Indications

    Indications

    Acute leukemia. In combination with other chemotherapeutic agents for Hodgkin's disease, non-Hodgkin's malignant lymphomas (lymphocytic, mixed-cell, histiocytic, undifferentiated, nodular, diffuse types).

    Vincristine Sulfate Pfs Dosage and Administration

    Adult

    Usual dose: 1.4mg/m2 IV once weekly. Serum bilirubin >3mg/100mL: reduce dose by 50%.

    Children

    ≤10kg: initially 0.05mg/kg IV once weekly. >10kg: usual dose: 2mg/m2 IV once weekly.

    Vincristine Sulfate Pfs Contraindications

    Contraindications

    Demyelinating form of Charcot-Marie-Tooth syndrome.

    Vincristine Sulfate Pfs Boxed Warnings

    Boxed Warning

    Should be administered by experienced individuals. For IV use only; fatal if given by other routes (eg, intrathecal).

    Vincristine Sulfate Pfs Warnings/Precautions

    Warnings/Precautions

    Pre-existing neuromuscular disease. Obtain CBCs, platelets before each dose, then periodically. Monitor serum uric acid levels during first 3–4 weeks of treatment. Avoid extravasation. Hepatic dysfunction. Pregnancy (Cat.D); avoid use. Nursing mothers: not recommended.

    Vincristine Sulfate Pfs Pharmacokinetics

    See Literature

    Vincristine Sulfate Pfs Interactions

    Interactions

    Concomitant radiotherapy through ports that include the liver: not recommended. Potentiated by CYP3A4 enzyme inhibitors (eg, itraconazole). Antagonizes phenytoin. Caution with other neurotoxic or platinum-containing agents. Separate L-asparaginase dose by 12–24hrs (administer after vincristine). Consider discontinuing drugs that cause urinary retention for the first few days following therapy.

    Vincristine Sulfate Pfs Adverse Reactions

    Adverse Reactions

    GI upset, paralytic ileus (esp. in children; discontinue temporarily if occurs), polyuria, dysuria, urinary retention, hypertension, hypotension, neuromuscular effects, dyspnea, bronchospasm, alopecia, rash, fever, headache, hypersensitivity reactions, acute uric acid nephropathy.

    Vincristine Sulfate Pfs Clinical Trials

    See Literature

    Vincristine Sulfate Pfs Note

    Notes

    Formerly known under the brand name Vincasar PFS.

    Vincristine Sulfate Pfs Patient Counseling

    See Literature

    • Latest News Your top articles for Wednesday

    • Haymarket Medical NetworkTop Picks

    • Loading...

      Continuing Medical Education (CME/CE) Courses

      Show More